Circulating immune complexes of Aβ and IgM in plasma of patients with Alzheimer’s disease

[1]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[2]  T. Schneider-Axmann,et al.  Effect of copper intake on CSF parameters in patients with mild Alzheimer’s disease: a pilot phase 2 clinical trial , 2008, Journal of Neural Transmission.

[3]  P. Pontisso,et al.  Tumour‐specific induction of immune complexes: DCP‐IgM in hepatocellular carcinoma , 2008, European journal of clinical investigation.

[4]  E. Matsubara,et al.  Plasma antibodies to Aβ40 and Aβ42 in patients with Alzheimer's disease and normal controls , 2008, Brain Research.

[5]  M. Shoji,et al.  Plasma biomarkers of Alzheimer's disease , 2008, Current opinion in psychiatry.

[6]  B. Hyman,et al.  Plasma Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men , 2008 .

[7]  B. Hyman,et al.  The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease , 2007, Neuroscience Letters.

[8]  U. Nydegger.  Immune Complex Pathophysiology , 2007, Annals of the New York Academy of Sciences.

[9]  R. Sewell,et al.  Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: Autoantibodies to Aβ(25–35) oligomers, S100b and neurotransmitters , 2007, Journal of Neuroimmunology.

[10]  R. Petersen,et al.  Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease , 2007 .

[11]  M. Yoshita,et al.  Blood-Brain Barrier Permeability Correlates with Medial Temporal Lobe Atrophy but Not with Amyloid-β Protein Transport across the Blood-Brain Barrier in Alzheimer’s Disease , 2007, Dementia and Geriatric Cognitive Disorders.

[12]  A. Hofman,et al.  Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study , 2006, The Lancet Neurology.

[13]  C. Mariani,et al.  Plasma levels of beta-amyloid (1–42) in Alzheimer's disease and mild cognitive impairment , 2006, Neurobiology of Aging.

[14]  P. Mehta,et al.  Increased Cerebrospinal Fluid Aβ38/Aβ42 Ratio in Alzheimer Disease , 2006, Neurodegenerative Diseases.

[15]  C. Belluco,et al.  Detection of Circulating CEA-IgM Complexes in Early Stage Colorectal Cancer , 2005, The International journal of biological markers.

[16]  J. Sidtis,et al.  Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[17]  P. Pontisso,et al.  Squamous cell carcinoma antigen‐immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma , 2005, Cancer.

[18]  N. Bogdanovic,et al.  Human monoclonal antibodies against amyloid-beta from healthy adults , 2005, Neurobiology of Aging.

[19]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[20]  R. Sewell,et al.  Autoimmune Responses to Amyloid Structures of Aβ(25–35) Peptide and Human Lysozyme in the Serum of Patients with Progressive Alzheimer’s Disease , 2004, Dementia and Geriatric Cognitive Disorders.

[21]  Kaj Blennow,et al.  Cerebrospinal fluid protein biomarkers for Alzheimer’s disease , 2004, NeuroRX.

[22]  P. Pontisso,et al.  Improvement of Liver Cancer Detection with Simultaneous Assessment of Circulating Levels of Free Alpha-Fetoprotein (AFP) and Afp-Igm Complexes , 2004, The International journal of biological markers.

[23]  Juan Manuel Maler,et al.  Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau , 2004, Neurobiology of Aging.

[24]  K. Blennow,et al.  Intrathecal inflammation precedes development of Alzheimer’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[25]  J. Growdon,et al.  Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels , 2003 .

[26]  K. Henke,et al.  Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease , 2003, Neuron.

[27]  H. Möller,et al.  Progressive loss of cardiac sympathetic innervation in Parkinson's disease , 2002, Annals of neurology.

[28]  N. Relkin,et al.  Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals , 2002, Experimental Gerontology.

[29]  E. Masliah,et al.  Absence of elevated anti–&agr;-synuclein and anti-EBV latent membrane protein antibodies in PD , 2002, Neurology.

[30]  Patrick L. McGeer,et al.  Inflammation, autotoxicity and Alzheimer disease , 2001, Neurobiology of Aging.

[31]  W. Oertel,et al.  Reduced levels of amyloid β-peptide antibody in Alzheimer disease , 2001, Neurology.

[32]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Y. Ihara,et al.  Alzheimer β Amyloid Deposition Enhanced by ApoE ϵ4 Gene Precedes Neurofibrillary Pathology in the Frontal Association Cortex of Nondemented Senior Subjects , 2001 .

[34]  B. Hyman,et al.  Autoantibodies to amyloid‐β and Alzheimer's disease , 2001, Annals of neurology.

[35]  P. Mehta,et al.  Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease , 2001, Neuroscience Letters.

[36]  K. Blennow,et al.  Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.

[37]  Hilkka Soininen,et al.  Relationship between apoE genotype and CSF β-amyloid (1–42) and tau in patients with probable and definite Alzheimer’s disease , 2000, Neurobiology of Aging.

[38]  D. Galasko,et al.  Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. , 2000, Biochemical and biophysical research communications.

[39]  K. Blennow,et al.  Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma , 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[40]  B Engvall,et al.  Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression , 1999, Annals of neurology.

[41]  E. Matsubara,et al.  Lipoprotein‐free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome , 1999, Annals of neurology.

[42]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[43]  J. Kaye,et al.  High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.

[44]  S. Hirai,et al.  Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan , 1998 .

[45]  J. Trojanowski,et al.  A new consensus report on biomarkers for the early antemortem diagnosis of Alzheimer disease: current status, relevance to drug discovery, and recommendations for future research. , 1998, Journal of neuropathology and experimental neurology.

[46]  F. Gaskin,et al.  Increased incidence of anti-β-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease , 1997, Mechanisms of Ageing and Development.

[47]  S. Tsuji,et al.  The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta 42(43) , 1997, Neurology.

[48]  B. Hyman,et al.  Amyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma* , 1996, The Journal of Biological Chemistry.

[49]  E. Oguni,et al.  Amyloid β protein in plasma from patients with sporadic Alzheimer's disease , 1996, Journal of the Neurological Sciences.

[50]  H. Lassmann,et al.  APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's Disease , 1996, Neurobiology of Aging.

[51]  S. Younkin,et al.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.

[52]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[53]  B. Hyman,et al.  Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. , 2008, Archives of neurology.

[54]  R. Petersen,et al.  Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. , 2007, Archives of neurology.

[55]  G. Fassina,et al.  Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients. , 2007, Cancer detection and prevention.

[56]  Charles D. Smith,et al.  Autoantibodies to amyloid β-peptide (Aβ) are increased in Alzheimer’s disease patients and Aβ antibodies can enhance Aβ neurotoxicity , 2007, NeuroMolecular Medicine.

[57]  A. Hofman,et al.  Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. , 2006, The Lancet. Neurology.

[58]  P. Mehta,et al.  Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer disease. , 2005, Neuro-degenerative diseases.

[59]  P. Lewczuk,et al.  Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. , 2004, Neurobiology of aging.

[60]  Charles D. Smith,et al.  Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. , 2003, Neuromolecular medicine.

[61]  J. Growdon,et al.  Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. , 2003, Archives of neurology.

[62]  K. Henke,et al.  Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. , 2003, Neuron.

[63]  Y. Ihara,et al.  Alzheimer beta amyloid deposition enhanced by apoE epsilon4 gene precedes neurofibrillary pathology in the frontal association cortex of nondemented senior subjects. , 2001, Journal of neuropathology and experimental neurology.

[64]  D. Holtzman,et al.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[65]  P. Mehta,et al.  Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. , 2001, Neuroscience letters.

[66]  H. Wiśniewski,et al.  Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease , 2000 .

[67]  S. Hirai,et al.  Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. , 1998, Annals of neurology.

[68]  V. Singh,et al.  Neuroautoimmunity: pathogenic implications for Alzheimer's disease. , 1997, Gerontology.

[69]  E. Oguni,et al.  Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. , 1996, Journal of the neurological sciences.